Safety and efficacy of combined use of low molecular weight heparin (enoxaparin, lovenox) and glycoprotein IIb/IIIa receptor antagonist (eptifibatide, integrelin) during nonemergent coronary and peripheral vascular intervention.

American journal of therapeutics

Volumn 9, Issue 6, 2002, Pages 488-491

  Khosla, Sandeep ^a   Kunjummen, Binu ^a   Guerrero, Mayra ^a   Manda, Ravi ^a   Razminia, Mansoor ^a   Trivedi, Atul ^a   Vidyarthi, Vasundhara ^a   Elbazour, Monther ^a   Ahmed, Aziz ^a   Lubell, David ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; PEPTIDE;

ARTICLE; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; COMORBIDITY; CORONARY DISEASE; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES;

EID: 0036833939     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200211000-00005     Document Type: Article

References (0)